Early HBeAg Loss During Peginterferon alpha-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients

Buster, Erik; Flink, Hajo; ŞİMŞEK, HALİS; Heathcote, E.; Sharmila, Sachithanandan; Kitis, George; Gerken, Guido; Buti, Maria; de Vries, Richard; Verhey, Elke; Hansen, Bettina; Janssen, Harry

doi:10.1038/ajg.2009.371

Early HBeAg Loss During Peginterferon alpha-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients

Buster E. H. C. J., Flink H. J., ŞİMŞEK H., Heathcote E. J., Sharmila S., Kitis G. E., ...Daha Fazla

AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.104, sa.10, ss.2449-2457, 2009 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 104 Sayı: 10
Basım Tarihi: 2009
Doi Numarası: 10.1038/ajg.2009.371
Dergi Adı: AMERICAN JOURNAL OF GASTROENTEROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2449-2457
Hacettepe Üniversitesi Adresli: Evet

Özet

OBJECTIVES: Treatment with pegylated interferon (PEG-IFN) alpha-2b results in hepatitis B e antigen (HBeAg) loss in 36% of patients at 6 months post treatment. The aim of this study was to determine whether a long-term response to PEG-IFN is dependent on the timing of HBeAg loss.